{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T02:26:01Z","timestamp":1700274361390},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1053\/beha.2002.0221","type":"journal-article","created":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T01:48:30Z","timestamp":1039571310000},"page":"467-480","source":"Crossref","is-referenced-by-count":4,"title":["High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma"],"prefix":"10.1053","volume":"15","author":[{"given":"Ama Z.S.","family":"Rohatiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beha.2002.0221_RF1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"Parma International Protocol-pilot study of DHAP followed by involved field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF2","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1200\/JCO.2002.09.138","article-title":"Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomised trial evaluating graft source and minimal residual disease","volume":"20","author":"Vose","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1701866","article-title":"Blood and marrow transplantation activity in Europe 1997","volume":"24","author":"Gratwohl","year":"1999","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0221_RF5","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.1994.12.12.2543","article-title":"Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients","volume":"12","author":"Haioun","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF6","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87-2 protocol\u2013a Group d'Etude des Lymphomes de l'Adulte Study","volume":"18","author":"Haioun","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF7","first-page":"594","article-title":"Failure of first-line inductive high dose chemotherapy in poor risk patients with aggressive lymphoma: updated results of the randomised LHN93-2 study","volume":"90","author":"Reyes","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomised phase III EORTC study","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1053\/beha.2002.0221_RF9","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VOCOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective trial by the non-Hodgkin's Lymphoma Cooperative study group","volume":"16","author":"Santini","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF10","unstructured":"Linch, D, C, A randomised trial of CHOP x 6 \u2013 8 vs CHOP x 3+BEAM+ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkin's lymphoma"},{"key":"10.1053\/beha.2002.0221_RF11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0221_RF12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1996.14.2.534","article-title":"High dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study","volume":"14","author":"Martelli","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma","volume":"332","author":"Verdonck","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0221_RF14","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.V74.7.2579.2579","article-title":"Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation","volume":"74","author":"Schouten","year":"1989","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF15","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1200\/JCO.1999.17.1.216","article-title":"Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow support for follicular lymphoma","volume":"17","author":"Apostolidis","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long term clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1008339921975","article-title":"The CUP trial: a randomised study analysing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)","volume":"11","author":"Schouten","year":"2000","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0221_RF20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/sj.bmt.1703294","article-title":"Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma","volume":"29","author":"Pettengell","year":"2002","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF21","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia (tMDS) and secondary acute myelogenous leukemia (sAML) following high-dose therapy (HDT) with autologous hematopoietic progenitor cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF23","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1994.12.12.2527","article-title":"Incidence and characterization of secondary myelodysplastic syndrome following high-dose, chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies","volume":"12","author":"Darrington","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF24","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V83.12.3780.3780","article-title":"Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy","volume":"83","author":"Miller","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF25","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.1994.12.12.2535","article-title":"Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"12","author":"Stone","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF26","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","article-title":"Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"17","author":"Friedberg","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1046\/j.1365-2141.1999.01627.x","article-title":"Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT","volume":"106","author":"Milligan","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0221_RF28","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","article-title":"All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment","volume":"78","author":"Gribben","year":"1991","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF29","first-page":"113","article-title":"Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification t(14;18) both pre-and post-treatment","volume":"7","author":"Berinstein","year":"1993","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0221_RF30","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/bjc.1991.482","article-title":"Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification","volume":"64","author":"Hickish","year":"1991","journal-title":"British Journal of Cancer"},{"key":"10.1053\/beha.2002.0221_RF31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(93)92560-G","article-title":"Gene-marking to trace origin of relapse after autologous bone-marrow transplantation","volume":"341","author":"Brenner","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/beha.2002.0221_RF32","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V83.10.3068.3068","article-title":"Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML","volume":"83","author":"Deisseroth","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bmt.1701051","article-title":"Should we purge?","volume":"21","author":"Bensinger","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF34","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.1998.16.8.2803","article-title":"Autologous stem cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy post transplantation\u2013results of a retrospective analysis on 120 patients autografted in a single institution","volume":"16","author":"Fouillard","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/stem.150297","article-title":"Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems","volume":"15","author":"Paulus","year":"1997","journal-title":"Stem Cells"},{"key":"10.1053\/beha.2002.0221_RF37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.bmt.1701612","article-title":"Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL)","volume":"23","author":"Martin-Henao","year":"1999","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.leu.2401488","article-title":"Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions","volume":"13","author":"Tarella","year":"1999","journal-title":"Leukaemia"},{"key":"10.1053\/beha.2002.0221_RF39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10428199609054834","article-title":"Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14:18) lymphoma cells","volume":"23","author":"Yerly-Motta","year":"1996","journal-title":"Leukemia & Lymphoma"},{"key":"10.1053\/beha.2002.0221_RF40","first-page":"1654","article-title":"High dose therapy improves outcome in relapsed follicular non-Hodgkin's lymphoma: results of a randomised clinical trial","volume":"414a","author":"Schouten","year":"2002","journal-title":"Proceedings of the American Society for Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF41","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","article-title":"Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma","volume":"86","author":"Bastion","year":"1995","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF42","first-page":"149","article-title":"High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma","volume":"17","author":"Haas","year":"1996","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF43","first-page":"1814","article-title":"Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation","volume":"94","author":"Abruzzese","year":"1999","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF44","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2001.19.9.2472","article-title":"Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukaemia after treatment for non-Hodgkin's lymphoma","volume":"19","author":"Lillington","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF45","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","article-title":"High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma","volume":"15","author":"Bierman","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF46","first-page":"121","article-title":"High dose chemotherapy as upfront treatment in 35 patients with indolent lymphoma induces a high rate of durable clinical and molecular remission","volume":"88","author":"Tarella","year":"1996","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1983.1.1.11","article-title":"Histologic conversion in the non-Hodgkin's lymphomas","volume":"1","author":"Acker","year":"1983","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y","article-title":"Histological transformation of non-Hodgkin's lymphoma. A prospective study","volume":"44","author":"Cullen","year":"1979","journal-title":"Cancer"},{"key":"10.1053\/beha.2002.0221_RF49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0609.1989.tb01205.x","article-title":"Follicular low-grade non-Hodgkin's lymphoma: long term outcome with or without tumor progression","volume":"42","author":"Ersboll","year":"1989","journal-title":"European Journal of Haematology"},{"key":"10.1053\/beha.2002.0221_RF50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V59.2.258.258","article-title":"Histologic progression in non-Hodgkin's lymphoma","volume":"59","author":"Hubbard","year":"1982","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF51","first-page":"413","article-title":"Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant","volume":"65","author":"Armitage","year":"1981","journal-title":"Cancer Treatment Reports"},{"key":"10.1053\/beha.2002.0221_RF52","first-page":"929","article-title":"Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival","volume":"65","author":"Ostrow","year":"1981","journal-title":"Cancer Treatment Reports"},{"key":"10.1053\/beha.2002.0221_RF53","first-page":"365 (abstr 1236)","article-title":"Long term survival after histologic transformation of low grade lymphoma","volume":"12","author":"Yuen","year":"1993","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008349427337","article-title":"High-dose therapy and autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre","volume":"9","author":"Foran","year":"1998","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0221_RF55","first-page":"727a","article-title":"Autologous bone marrow transplantation following histologic transformation of indolent B cell non-Hodgkin's lymphoma","volume":"92","author":"Friedberg","year":"1998","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF56","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","article-title":"Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma","volume":"113","author":"Chen","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0221_RF57","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF58","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF59","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","article-title":"A UK multicentre Phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response","volume":"109","author":"Foran","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0221_RF62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF63","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2141.2000.02084.x","article-title":"In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma","volume":"109","author":"Voso","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0221_RF64","first-page":"115","article-title":"Stem cell function and engraftment is not affected by \u2018in vivo purging\u2019 with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma","volume":"5","author":"Buckstein","year":"1999","journal-title":"Seminars in Oncology"},{"key":"10.1053\/beha.2002.0221_RF65","first-page":"141a","article-title":"In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts)","volume":"94","author":"Salles","year":"1999","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF66","first-page":"674a","article-title":"Clinical characteristics and response to chemotherapy of mantle cell lymphomas-results of a European survey","volume":"88","author":"Hiddeman","year":"1996","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF67","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2559.2000.00895.x","article-title":"The World Health Organisation classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997","volume":"36","author":"Harris","year":"2000","journal-title":"Histopathology"},{"key":"10.1053\/beha.2002.0221_RF69","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF70","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood.V86.7.2715.2715","article-title":"Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma","volume":"86","author":"de Boer","year":"1995","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/oxfordjournals.annonc.a059154","article-title":"Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20 year period","volume":"6","author":"Norton","year":"1995","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0221_RF72","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0221_RF73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1701046","article-title":"High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients","volume":"21","author":"Blay","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF74","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF76","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF77","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF78","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0221_RF79","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","article-title":"Rituximab: enhancing stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Gianni","year":"2002","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0221_RF80","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","volume":"19","author":"Soussain","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0221_RF81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/10428199909145715","article-title":"The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single centre","volume":"35","author":"Fanin","year":"1999","journal-title":"Leukemia & Lymphoma"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602902215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602902215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T15:53:37Z","timestamp":1583942017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692602902215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1521692602902215"],"URL":"https:\/\/doi.org\/10.1053\/beha.2002.0221","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}